One-week once-daily triple therapy with esomeprazole, levofloxacin and azithromycin compared to a standard therapy for Helicobacter pylori eradication

Digestive and Liver Disease

Volumn 37, Issue 8, 2005, Pages 571-576

  Iacopini, F ^a   Crispino, P ^a   Paoluzi, O A ^a   Consolazio, A ^a   Pica, R ^a   Rivera, M ^a   Palladini, D ^a   Nardi, F ^a   Paoluzi, P ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Azithromycin; H. pylori; Levofloxacin

Indexed keywords

AMOXICILLIN; AZITHROMYCIN; BACTERIAL ANTIGEN; CLARITHROMYCIN; ESOMEPRAZOLE; LEVOFLOXACIN; UREA; ANTIINFECTIVE AGENT; ANTIULCER AGENT; OFLOXACIN; OMEPRAZOLE;

ABDOMINAL PAIN; ADULT; ALCOHOL CONSUMPTION; ARTICLE; BLOATING; CIGARETTE SMOKING; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REGIMEN; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ERADICATION THERAPY; FECES ANALYSIS; FEMALE; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PATIENT COMPLIANCE; PEPTIC ULCER; RANDOMIZED CONTROLLED TRIAL; TASTE DISORDER; TREATMENT DURATION; TREATMENT OUTCOME; UREA BREATH TEST; DRUG ADMINISTRATION; DRUG COMBINATION; MIDDLE AGED; STATISTICS;

ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; AZITHROMYCIN; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; OFLOXACIN; OMEPRAZOLE; PATIENT COMPLIANCE; TREATMENT OUTCOME;

EID: 28944441708     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2005.03.007     Document Type: Article

References (53)

1. Malfertheiner P., et al., European Helicobacter Pylori Study Group (EHPSG). Current concepts in the management of Helicobacter pylori infection. The Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 16 (2002) 167-180
2. Howden C.W., and Hunt R.H. Guidelines for the management of Helicobacter pylori infection. Am J Gastroenterol 93 (1998) 2330-2338
3. Dore M.P., Leandro G., Realdi G., Sepulveda A.R., and Graham D.Y. Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach. Dig Dis Sci 45 (2000) 67-68
4. Al-Eidan F.A., McElnay J.C., Scott M.G., and McConnell J.B. Management of Helicobacter pylori eradication - the influence of structured counseling and follow-up. Br J Clin Pharmacol 53 (2002) 163-171
5. Qasim A., and O'Morain C.A. Review article: treatment of Helicobacter pylori infection and factors influencing eradication. Aliment Pharmacol Ther 16 Suppl. 1 (2002) 24-30
6. Bertoni G., Sassatelli R., Nigrisoli E., Tansini P., Bianchi G., Della Casa G., et al. Triple therapy with azithromycin, omeprazole, and amoxicillin is highly effective in the eradication of Helicobacter pylori: a controlled trial versus omeprazole plus clarithromycin. Am J Gastroenterol 91 (1996) 258-263
7. Di Caro S., Assunta Zocco M., Cremonini F., Candelli M., Nista E.C., Bartolozzi F., et al. Levofloxacin based regimens for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 14 (2002) 1309-1312
8. Gatta L., Ricci C., Tampieri A., and Vaira D. Non-invasive techniques for the diagnosis of Helicobacter pylori infection. Clin Microbiol Infect 9 (2003) 489-496
9. de Boer W.A., Thys J.C., Borody T.J., Graham D.Y., O'Morain C., and Tytgat G.N. Proposal for use of standard side effects scoring system in studies exploring Helicobacter pylori treatment. Eur J Gastroenterol Hepatol 8 (1996) 641-643
10. Loffeld R.J., and Fijen C.A. Antibiotic resistance of Helicobacter pylori: a cross sectional study in consecutive patients, and relation to ethnicity. Clin Microbiol Infect 9 (2003) 600-604
11. Gambaro C., Bilardi C., Dulbecco P., Iiritano E., Zentilin P., Mansia C., et al. Comparable Helicobacter pylori eradication rates obtained with 4- and 7-day rabeprazole-based triple therapy: a preliminary study. Dig Liver Dis 35 (2003) 763-767
12. Laine L., Estrada R., Trujillo M., Cheybani K., Yeramian P., Smith S., et al. Once-daily therapy for Helicobacter pylori infection: a randomized comparison of four regimens. Am J Gastroenterol 94 (1999) 962-966
13. Chu K.-M., Kwok K.-F., Law S.Y.K., and Wong J. One-week once-daily triple therapy for Helicobacter pylori - a pilot study. Hepatogastroenterology 47 (2000) 1624-1626
14. Wheeldon T.U., Hoang T.T.H., Phung D.C., Bjorkman A., Granstrom M., and Sorberg M. Helicobacter pylori eradication and peptic ulcer healing: the impact of deleting the proton pump inhibitor and using a once-daily treatment. Aliment Pharmacol Ther 18 (2003) 93-100
15. Coelho L.G., Martins G.M., Passos M.C., Bueno M.L., Sanches B.S., Lopes L.G., et al. Once-daily, low-cost, highly effective Helicobacter pylori treatment to family members of gastric cancer patients. Aliment Pharmacol Ther 17 (2003) 131-136
16. Cammarota G., Cianci R., Cannizzaro O., Martino A., Fedeli P., Lecca P.G., et al. High-dose versus low-dose clarithromycin in 1-week triple therapy, including rabeprazole and levofloxacin, for Helicobacter pylori eradication. J Clin Gastroenterol 38 (2004) 110-114
17. Watanabe Y., Aoyama N., Shirasaka D., Maekawa S., Kuroda K., Miki I., et al. Levofloxacin based triple therapy as a second-line treatment after failure of Helicobacter pylori eradication with standard triple therapy. Dig Liver Dis 35 (2003) 711-715
18. Wong W.M., Gu Q., Lam S.K., Fung F.M., Lai K.C., Hu W.H., et al. Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection. Aliment Pharmacol Ther 17 (2003) 553-560
19. Cammarota G., Martino A., Pirozzi G., Cianci R., Branca G., Nista E.C., et al. High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection. Aliment Pharmacol Ther 19 (2004) 789-795
20. Calabrese C., Di Febo G., Areni A., Scialpi C., Biasco G., and Miglioli M. Pantoprazole, azithromycin and tinidazole: short duration triple therapy for eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 14 (2000) 1613-1617
21. Vcev A., Stimac D., Vceva A., Takac B., Pezerovic D., and Ivandic A. High dose omeprazole plus amoxicillin and azithromycin in eradication of Helicobacter pylori in duodenal ulcers. Helicobacter 4 (1999) 54-57
22. Osato M.S., Reddy S.G., Piergies A.A., Bochenek W.J., Testa R.T., and Graham D.Y. Comparative efficacy of new investigational agents against Helicobacter pylori. Aliment Pharmacol Ther 15 (2001) 487-492
23. Trautmann M., Riediger C., Moricke A., Vogt K., Bohr U., and Glasbrenner B. Combined activity of azithromycin and lansoprazole against Helicobacter pylori. Helicobacter 4 (1999) 113-120
24. Boyanova L., Koumanova R., Gergova G., Popova M., Mitov I., Kovacheva Y., et al. Prevalence of resistant Helicobacter pylori isolates in Bulgarian children. J Med Microbiol 51 (2002) 786-790
25. Kato S., Fujimura S., Udagawa H., Shimizu T., Maisawa S., Ozawa K., et al. Antibiotic resistance of Helicobacter pylori strains in Japanese children. J Clin Microbiol 40 (2002) 649-653
26. Hamasaki N., Ishii E., Tominaga K., Tezuka Y., Nagaoka T., Kadota S., et al. Highly selective antibacterial activity of novel alkyl quinolone alkaloids from a Chinese herbal medicine, Gosyuyu (Whu-Chu-Yu), against Helicobacter pylori. Microbiol Immunol 44 (2000) 9-15
27. Blandizzi C., Malizia T., Gherardi G., Costa F., Marchi S., Marveggio C., et al. Gastric mucosal distribution and clinical efficacy of azithromycin in patients with Helicobacter pylori related gastritis. J Antimicrob Chemother 42 (1998) 75-82
28. Savarino V., Zentilin P., Bisso G., Pivari M., Mele M.R., Mela G.S., et al. Head-to-head comparison of 1-week triple regimens combining ranitidine or omeprazole with two antibiotics to eradicate Helicobacter pylori. Aliment Pharmacol Ther 13 (1999) 643-649
29. Laurent J., Megraud F., Flejou J.F., Caekaert A., and Barthelemy P. A randomized comparison of four omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. Aliment Pharmacol Ther 15 (2001) 1787-1793
30. Gumurdulu Y., Serin E., Ozer B., Kayaselcuk F., Ozsahin K., Cosar A.M., et al. Low eradication rate of Helicobacter pylori with triple 7-14 days and quadruple therapy in Turkey. World J Gastroenterol 10 (2004) 668-671
31. Altintas E., Sezgin O., Ulu O., Aydin O., and Camdeviren H. Maastricht II treatment scheme and efficacy of different proton pump inhibitors in eradicating Helicobacter pylori. World J Gastroenterol 10 (2004) 1656-1658
32. Neri M., Milano A., Laterza F., Di Bonaventura G., Piccolomini R., Caldarella M.P., et al. Role of antibiotic sensitivity testing before first-line Helicobacter pylori eradication treatments. Aliment Pharmacol Ther 18 (2003) 821-827
33. Della Monica P., Lavagna A., Masoero G., Lombardo L., Crocella L., and Pera A. Effectiveness of Helicobacter pylori eradication treatments in a primary care setting in Italy. Aliment Pharmacol Ther 16 (2002) 1269-1275
34. Fini L., Nista E.C., Candelli M., Cazzato I.A., Franceschi F., Santoro M., et al. First-line treatment for Helicobacter pylori eradication: levofloxacin/azithromycin-based strategies. Helicobacter 9 (2004) A571
35. Laheij R.J., Rossum L.G., Jansen J.B., Straatman H., and Verbeek A.L. Evaluation of treatments to cure Helicobacter pylori infection - a meta-analysis. Aliment Pharmacol Ther 13 (1999) 857-864
36. Paoluzi P., Iacopini F., Consolazio A., Paoluzi O.A., Rossi P., Rivera M., et al. Two week triple teraphy with amoxycillin and clarithromycin has an higher efficacy in Helicobacter pylori eradication. Gut 49 Suppl. 3 (2001) A2545
37. Fini L., Nista E.C., Candelli M., Cazzato I.A., Santoro M., Finizio R., et al. 10 days levofloxacin-based triple therapy in second-line treatment for Helicobacter pylori eradication. Helicobacter 9 (2004) A573
38. Working Party of the European Helicobacter Pylori Study Group. Technical annex: tests used to assess Helicobacter pylori infection. In: Guidelines for clinical trials in Helicobacter pylori infection. Gut 1997;41(Suppl. 2):S10-8.
39. Kim J.J., Kim J.G., and Kwon D.H. Mixed-infection of antibiotic susceptible and resistant Helicobacter pylori isolates in a single patient and underestimation of antimicrobial susceptibility testing. Helicobacter 8 (2003) 202-206
40. Masuda H., Hiyama T., Yoshihara M., Tanaka S., Shimamoto F., Haruma K., et al. Necessity of multiple gastric biopsies from different sites for detection of clarithromycin-resistant Helicobacter pylori strains. Scand J Gastroenterol 38 (2003) 942-946
41. Iovene M.R., Romano M., Pilloni A.P., Giordano B., Montella F., Caliendo S., et al. Prevalence of antimicrobial resistance in eighty clinical isolates of Helicobacter pylori. Chemotherapy 45 (1999) 8-14
42. Toracchio S., Cellini L., Di Campli E., Cappello G., Malatesta M.G., Ferri A., et al. Role of antimicrobial susceptibility testing on efficacy of triple therapy in Helicobacter pylori eradication. Aliment Pharmacol Ther 14 (2000) 1639-1643
43. Toracchio S., and Marzio L. Primary and secondary antibiotic resistance of Helicobacter pylori strains isolated in central Italy during the years 1998-2002. Dig Liver Dis 35 (2003) 541-545
44. Dent J. Review article: pharmacology of esomeprazole and comparisons with omeprazole. Aliment Pharmacol Ther 17 Suppl. 1 (2003) 5-9
45. Vallve M., Vergara M., Gisbert J.P., and Calvet X. Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis. Aliment Pharmacol Ther 16 (2002) 1149-1156
46. Gisbert J.P., Marcos S., Gisbert J.L., and Pajares J.M. Helicobacter pylori eradication therapy is more effective in peptic ulcer than in non-ulcer dyspepsia. Eur J Gastroenterol Hepatol 13 (2001) 1303-1307
47. De Francesco V., Zullo A., Hassan C., Della Valle N., Pietrini L., Minenna M.F., et al. The prolongation of triple therapy for Helicobacter pylori does not allow reaching therapeutic outcome of sequential scheme: a prospective, randomised study. Dig Liver Dis 36 (2004) 322-326
48. Pilotto A., et al., Interdisciplinary Group for the Study of Ulcer. Prevalence of Helicobacter pylori resistance to antibiotics in Northeast Italy: a multicentre study. GISU. Interdisciplinary Group for the Study of Ulcer. Dig Liver Dis 32 (2000) 763-768
49. De Boer W.A., and Tytgat G.N.J. Should anti-Helicobacter therapy be different in patients with dyspepsia compared with patients with peptic ulcer diathesis?. Eur J Gastroenterol Hepatol 13 (2001) 1281-1284
50. Dore M.P., Graham D.Y., Mele R., Marras L., Nieddu S., Manca A., et al. Colloidal bismuth subcitrate-based twice-a-day quadruple therapy as primary or salvage therapy for Helicobacter pylori infection. Am J Gastroenterol 97 (2002) 857-860
51. Perri F., Villani M.R., Festa V., Quitadamo M., and Andriulli A. Predictors of failure of Helicobacter pylori eradication with the standard 'Maastricht triple therapy'. Aliment Pharmacol Ther 15 (2001) 1023-1029
52. Queiroz D.M., Dani R., Silva L.D., Santos A., Moreira L.S., Rocha G.A., et al. Factors associated with treatment failure of Helicobacter pylori infection in a developing country. J Clin Gastroenterol 35 (2002) 315-320
53. Boixeda D., Bermejo F., Martin-De-Argila C., Lopez-Sanroman A., Defarges V., Hernandez-Ranz F., et al. Efficacy of quadruple therapy with pantoprazole, bismuth, tetracycline and metronidazole as rescue treatment for Helicobacter pylori infection. Aliment Pharmacol Ther 16 (2002) 1457-1460